Skip to main content
SpringerLink
Log in

Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis

  • Original article
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Treatment of systemic-onset juvenile idiopathic arthritis (So-JIA) is challenging, and the efficacy of injectable recombinant human tumor necrosis factor type 1 receptor-antibody fusion protein (etanercept) on So-JIA has been controversial.

Methods

We retrospectively studied 12 patients with refractory systemic juvenile arthritis treated with etanercept at our hospital in the past 5 years. The 12 patients were divided into a corticosteroid-dependent group (n=7) and an ineffective group (n=5) on the basis of their responses to treatment before the administration of etanercept. Etanercept was added to the treatment without substantially changing the original regimens in general, and doses, and signs of efficacy including alleviation or resolution of symptoms such as high fever, inflammatory arthropathy, eruption rash, hydrohymenitis, as well as changes in the levels of laboratory inflammatory markers such as the white blood cell count, erythrocyte sedimentation rate, levels of C-reactive protein and serum ferritin were recorded.

Results

Etanercept was withdrawn after the first dose from one patient in the corticosteroid-dependent group because of a systemic allergic rash, and was also withdrawn from one patient in the ineffective group after 2 months of treatment owing to inefficacy; the remaining 10 patients completed the entire treatment protocol, at which point etanercept was discontinued. At that time, clinical symptoms and laboratory inflammatory markers of the remaining patients were within the normal range and the mean dose of prednisone was 0.18 mg/kg per day, an 81% decrease from the mean dose at baseline. At present, the corticosteroid has been discontinued and only methotrexate maintenance treatment is used in 3 patients; the other 7 patients are treated with prednisone and methotrexate maintenance therapy. All of the 10 patients are in a medicated remission with no recurrence.

Conclusions

In the treatment of patients with refractory So-JIA, the principles of individual therapy and combinations of drugs should be followed. Etanercept is an important and valid candidate for use in such combined treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cassidy JT, Petty RE. Textbook of pediatric rheumatology, 5th ed. Philadelphia: Saunders, 2005.

    Google Scholar 

  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767–778.

    Article  PubMed  CAS  Google Scholar 

  3. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491–496.

    PubMed  CAS  Google Scholar 

  4. Kahn P. Juvenile idiopathic arthritis—current and future therapies. Bull NYU Hosp Jt Dis 2009;67:291–302.

    PubMed  Google Scholar 

  5. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for newonset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012;64:1001–1010.

    CAS  Google Scholar 

  6. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1852–1855.

    Article  PubMed  CAS  Google Scholar 

  7. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 2001;40:907–913.

    Article  CAS  Google Scholar 

  8. Wulffraat NM, Sanders LA, Kuis W. Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000;2:316–323.

    Article  PubMed  CAS  Google Scholar 

  9. Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005;17:612–616.

    Article  PubMed  CAS  Google Scholar 

  10. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093–1101.

    Article  PubMed  CAS  Google Scholar 

  11. Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 2005;23:545–548.

    PubMed  CAS  Google Scholar 

  12. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479–1486.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebocontrolled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747–754.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071–2075.

    PubMed  Google Scholar 

  15. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638–1644.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014;41:759–767.

    Article  PubMed  CAS  Google Scholar 

  17. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemiconset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998–1006.

    Article  PubMed  CAS  Google Scholar 

  18. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–2395.

    Article  PubMed  CAS  Google Scholar 

  19. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290–2294.

    PubMed  Google Scholar 

  20. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935–942.

    PubMed  CAS  Google Scholar 

  21. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube M, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392–2401.

    Article  PubMed  Google Scholar 

  22. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989–1999.

    PubMed  Google Scholar 

  23. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003;30:401–403.

    PubMed  Google Scholar 

  24. Murdaca G, Spanò F, Contatore M, Guastalla A, Magnani O, Puppo F. Efficacy and safety of etanercept in chronic immunemediated disease. Expert Opin Drug Saf 2014;13:649–661.

    Article  PubMed  CAS  Google Scholar 

  25. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 2012;11:1–5.

    Article  PubMed  CAS  Google Scholar 

  26. Murdaca G, Spanò F, Puppo F. Selective TNF-a inhibitorinduced injection site reactions. Expert Opin Drug Saf 2013;12:187–193.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Shanghai Children’s Medical Center, Shanghai Jiaotong University, School of Medicine, Shanghai, China

    Xiao Hu, Fang Yuan, Jian Zhang, Lei Yin, Bi-Ru Li & Yan-Liang Jin

Authors
  1. Xiao Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bi-Ru Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan-Liang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan-Liang Jin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, X., Yuan, F., Zhang, J. et al. Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis. World J Pediatr 12, 96–102 (2016). https://doi.org/10.1007/s12519-015-0009-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-015-0009-3

Key words

Search

Navigation